Latest Industry Insights
Industry Insight
Exploring Plant-Based Bioreactors for Developing COVID-19 Therapeutics and Vaccines
Technology Networks recently spoke with iBio’s CEO and Chairman of the Board Thomas Isett, to learn more about the company’s efforts to develop a novel COVID-19 therapeutic called ACE2-Fc, as well as two vaccine candidates IBIO-200 and IBIO-201.
Industry Insight
Can You Achieve Rapid MS Analysis With No Sample Prep?
News of how innovations can assist scientists and their workflows is not uncommon, but claims of “industry revolutions”, however, tend to be a little less frequent. The Echo® MS System from SCIEX is touted as being one such revolution, we spoke to Neil Walsh to learn more.
Industry Insight
A Smarter Way To Remove Host Cell Protein Contamination From Gene Therapies
In this piece, Ejvind Mørtz and Todd Stawicki explain why it’s critical that gene therapy products are free of host cell proteins and how this can be ensured in the production process, so that these next-generation drugs can fulfil their potential as one-shot cures for a range of diseases, from rare genetic conditions to cancer.
Industry Insight
Tapping Into Information Locked in Our T Cells To Fight COVID-19
T cells are an important part of our immune memory and offer a wealth of valuable information about the way our bodies perceive and respond to pathogens. Learn how this information is being harnessed and applied in the fight against COVID-19.
Industry Insight
Harnessing Human Skin Models for Drug Development
We recently spoke with Pascal Descargues, CEO at Genoskin to learn more about the legal restrictions on animal testing and how human skin tissue can be used as an alternative.
Industry Insight
Exploring the Technology Behind a Blood Test for Alzheimer's Disease
Technology Networks recently spoke to Quanterix's Kevin Hrusovsky to hear more about how the company's technology is being applied in the pursuit of a biomarker for Alzheimer's disease, a progressive neurodegenerative condition for which diagnosis often occurs after the onset of symptoms.
Industry Insight
Biomaterial-Based Vaccine That Sits Under the Skin Shows Promise Against SARS-CoV-2
A team of multidisciplinary scientists – including bioengineers, materials-scientists and immunologists – at the Wyss Institute has created a novel infection vaccine platform know as OmniVax. Technology Networks spoke with Lead Senior Staff Scientist Ed Doherty from the Wyss Institute for Biologically Inspired Engineering at Harvard University, to learn more.
Industry Insight
Scripps Research Spin-Off Ushers a "New Era" in Vaccinology With Platform Technology
Scripps Research spin-off company Ufovax employs the single-component self-assembling protein nanoparticle (1c-SApNP®) platform technology, that was created in the laboratory of Professor Jiang Zhu, to address some of the key challenges in modern vaccine development. We spoke with Dr. Colette Saccomanno to learn more.
Industry Insight
Progress in Stem Cell Therapy for Transplant, Stroke and ARDS Patients
Technology Networks spoke with Gil Van Bokkelen, CEO of Athersys, to learn more about MultiStem and the main mechanisms of action the cells have on the body. Gil also discussed some of the additional indications that the cells are being investigated as potential therapies for, including ischemic stroke and acute respiratory distress syndrome (ARDS).
Industry Insight
"Technology Dance" Looks Set To Transform the Field of DNA Synthesis
Codexis and Molecular Assemblies recently announced a partnership through which the companies aim to engineer enzymes that will optimize the process of enzymatic DNA synthesis – an alternative approach to chemical DNA synthesis. Technology Networks spoke with Codexis to find out how this will transform the field of DNA synthesis.
Advertisement